These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25963988)

  • 41. Safety and pharmacokinetics of repeat-dose micafungin in young infants.
    Benjamin DK; Smith PB; Arrieta A; Castro L; Sánchez PJ; Kaufman D; Arnold LJ; Kovanda LL; Sawamoto T; Buell DN; Hope WW; Walsh TJ
    Clin Pharmacol Ther; 2010 Jan; 87(1):93-9. PubMed ID: 19890251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
    Grau S; Luque S; Campillo N; Samsó E; Rodríguez U; García-Bernedo CA; Salas E; Sharma R; Hope WW; Roberts JA
    J Antimicrob Chemother; 2015 Oct; 70(10):2854-61. PubMed ID: 26180134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
    Dupont BF; Lortholary O; Ostrosky-Zeichner L; Stucker F; Yeldandi V
    Crit Care; 2009; 13(5):R159. PubMed ID: 19804626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
    Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
    Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
    Andes DR; Reynolds DK; Van Wart SA; Lepak AJ; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5714-6. PubMed ID: 23959319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.
    Chandra S; Fukuda T; Mizuno K; Davies SM; Teusink-Cross A; Tarin R; Marsh RA; Vinks AA; Mehta PA
    J Antimicrob Chemother; 2018 Jun; 73(6):1651-1658. PubMed ID: 29481593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
    Albano E; Azie N; Roy M; Townsend R; Arrieta A
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
    Würthwein G; Young C; Lanvers-Kaminsky C; Hempel G; Trame MN; Schwerdtfeger R; Ostermann H; Heinz WJ; Cornely OA; Kolve H; Boos J; Silling G; Groll AH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):536-43. PubMed ID: 22083471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative pharmacokinetics of the three echinocandins in ICU patients.
    Mainas E; Apostolopoulou O; Siopi M; Apostolidi S; Neroutsos E; Mirfendereski H; Marchand S; Couet W; Dokoumetzidis A; Valsami G; Sambatakou H; Dimopoulos G; Meletiadis J
    J Antimicrob Chemother; 2020 Oct; 75(10):2969-2976. PubMed ID: 32696036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.
    Bailly S; Gautier-Veyret E; Lê MP; Bouadma L; Andremont O; Neuville M; Mourvillier B; Sonneville R; Magalhaes E; Lebut J; Radjou A; Smonig R; Wolff M; Massias L; Dupuis C; Timsit JF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.
    Sime FB; Stuart J; Butler J; Starr T; Wallis SC; Pandey S; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.
    Grau S; Luque S; Echeverría-Esnal D; Sorlí L; Campillo N; Montero M; Álvarez Lerma F; Plasencia V; Horcajada JP
    Int J Antimicrob Agents; 2016 Aug; 48(2):212-4. PubMed ID: 27424599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
    Catalán-González M; Carlos Montejo-González J
    Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.
    Neofytos D; Huang YT; Cheng K; Cohen N; Perales MA; Barker J; Giralt S; Jakubowski A; Papanicolaou G
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S652-61. PubMed ID: 26567284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intraocular penetration of intravenous micafungin in inflamed human eyes.
    Mochizuki K; Sawada A; Suemori S; Kawakami H; Niwa Y; Kondo Y; Ohkusu K; Yamada N; Ogura S; Yaguchi T; Nishimura K; Kishino S
    Antimicrob Agents Chemother; 2013 Aug; 57(8):4027-30. PubMed ID: 23689706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.